Upload
rinky25
View
193
Download
1
Tags:
Embed Size (px)
Citation preview
Exploitation Plan for BE25
BEinEIMRT
CESGAJune 2009
Business Experiments in GRID2
Contents
1. Background
2. Service
3. Target customer and target market
4. Competition
5. Distribution and promotion strategies
6. Value network
7. Alliances and partnership
8. Implementation calendar
9. Pricing strategy
10. Financial aspects
11. Legal Aspects
12. Conclusions
Business Experiments in GRID3
Background
• Business sector: Health and Radiotherapy• Needs:
– Verify/improve quality of the treatments– The hospitals have to reduce costs– Reduced number of radiotherapists and very busy– Monte Carlo is a must for the future. But needs a lot of
computing.• Example:
– Verification:
• NOW: Stop LINAC/Make Measurements/Validate Measurement. Expensive
• FUTURE: Virtual verification. Faster, cheaper and simpler.– Optimization:
• NOW: Several days for ONE IMRT treatment plan• FUTURE: Less than half day
Business Experiments in GRID4
Service
e-IMRT is SaaS Verification service Optimization service
Innovation: Remote computing New Monte Carlo Linac commisioning Verification with 3D gamma maps Easy interface Flexibility New business model in radiotherapy
Business Experiments in GRID5
Target customer & Target market
RT Centers in EU
0 50 100 150 200 250
Luxembourg
Malta
Republic of Slovenia
Cyprus
Estonia
Latvia
Lithuania
Denmark
Finland
Republic of Ireland
Bulgaria
Portugal
Austria
Hungary
Slovak Republic
Romania
Sw eden
Netherlands
Belgium
Poland
Czech Republic
United Kingdom
Spain
Italy
France
Germany
Co
un
try
Number of Centers
There are 6214 radiotherapy centers in the world, with 7168 Linacs and more than 6000 TPS European Union: 980 radiotherapy institutions Other countries: USA (1870), China (981) and Japan (842) First customer: Spanish hospital
Business Experiments in GRID6
Target customer & Target market
Business Experiments in GRID7
Competition
Business Experiments in GRID8
Distribution and promotion strategies
Distribution.
Direct selling White brand
Promotion
Open sourceTechnical conferences (ESTRO, World
Congress, etc) and journalsDirect targeted marketing (Meixoeiro,
Herlev)Demo version (free) and video on Internet
Business Experiments in GRID9
USP
Monte Carlo at your finger tips. Effectiveness and quality of the final treatments. More productivity, have more time for other patient care. Let the system do some of the work for you. Secure and trustworthy The personal data of your patients will NEVER be outside
your institution. Very easy of use because uses the same navigator as you
use. You do not have to change your current TPS. We will work
with it. No software installation or maintenance. No initial investment: you only pay for as much as you
need.
Business Experiments in GRID10
Value network
End UserApplication
Provider
ResourceProvider
Tech. Provider
Service
Payment
Validation
Multiplicator
Know-how
Grid Service
Technology
Business Experiments in GRID12
Alliances and partnerships
Hospitals for testing The accelerator manufacturers (as Varian) Software providers (as BEAMnrc) Hardware and Grid providers (CPU cycles on demand) Treatment Planning Systems providers
Business Experiments in GRID13
Implementation calendar
AT CESGA
Spin-off
?
Business Experiments in GRID14
Financial aspects: pricing strategy
e-IMRT as remote service.
Pay-per-use model Price per treatment in verification
(100€/treatment)Price in units for optimization (100€/unit)
Hospital annual fee Added value services
DeploymentTraining
Business Experiments in GRID15
0,0100,0
200,0300,0
400,0500,0
600,0700,0
800,0900,0
1 2 3 4 5
YEAR
k€
Revenues
Costs
Financial Aspects
Break even point
Y1 Y2 Y3 Y4 Y5
EBITDA % -90% -68% -99% 117% 241%
ROI -277% 182% 72% 1721% 115%
Business Experiments in GRID16
Legal Aspects
Software licenses– BEAMnrc. Negotiating
– MCDOSE. Denied. Need replacement
– BEinEIMRT software. Will be open source soon.
No patent or other IP Legal agreements with customers Agreements with CPU providers Outsourcing billing and taxes management No health and personal data handled Legal regulation: 2007/47/EC which modifies 93/42/EEC CE Mark, FDA Clearance. No mandatory but convenient. ISO 9001:2008 Certification
Business Experiments in GRID17
Conclusion
Proof-of-concept is valid Start at CESGA soon. Externalize asap Business could be profitable in three years Still work to do Strong competitors Big and complex market R+D is a must for new company Legal regulation is a high barrier
© BEinGRID Consortium
THANK YOU
Any questions?